Emerging Trials in Pancreatic Cancer
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Emerging Trials in Pancreatic Cancer
-
ナレーター：
-
著者：
With one new drug against the KRAS mutation on the path to FDA approval, what is the status of other KRAS drugs, as well as different types of treatment?
To get the latest information, host Alisyn Camerota is joined once again by Dr. Allyson Ocean, medical oncologist and director of the Pancreatic Cancer Research Program at Weill Cornell Medicine, and a co-founder of Let's Win, along with Dr. Anna Berkenblit, Chief Scientific and Medical Officer for PanCAN, who brings more than two decades of experience in the research and clinical development of novel anticancer therapies.
Together, they discuss the status of pancreatic cancer vaccine research, walk through what a drug's journey from idea to approval actually looks like, and explain in plain terms what separates a phase 1 clinical trial from a phase 2 or phase 3 trial — and why every phase matters for patients considering enrollment.
This episode is brought to you by our sponsor, Revolution Medicines.
To learn more about the latest breakthroughs in pancreatic cancer treatment, visit letswinpc.org and pancan.org.
PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.